Cargando…

Multiscale Model Identifies Improved Schedule for Treatment of Acute Myeloid Leukemia In Vitro With the Mcl‐1 Inhibitor AZD5991

Anticancer efficacy is driven not only by dose but also by frequency and duration of treatment. We describe a multiscale model combining cell cycle, cellular heterogeneity of B‐cell lymphoma 2 family proteins, and pharmacology of AZD5991, a potent small‐molecule inhibitor of myeloid cell leukemia 1...

Descripción completa

Detalles Bibliográficos
Autores principales:	Goliaei, Ardeshir, Woods, Haley A., Tron, Adriana E., Belmonte, Matthew A., Secrist, J. Paul, Ferguson, Douglas, Drew, Lisa, Fretland, Adrian J., Aldridge, Bree B., Gibbons, Francis D.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2020
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7577016/ https://www.ncbi.nlm.nih.gov/pubmed/32860732 http://dx.doi.org/10.1002/psp4.12552

Ejemplares similares

Discovery of Mcl-1-specific inhibitor AZD5991 and preclinical activity in multiple myeloma and acute myeloid leukemia
por: Tron, Adriana E., et al.
Publicado: (2018)

P579: SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PRELIMINARY ANTITUMOR ACTIVITY OF AZD5991 IN RELAPSED/ REFRACTORY HEMATOLOGIC MALIGNANCIES: A PHASE 1 FIRST-IN-HUMAN STUDY
por: Desai, Pinkal, et al.
Publicado: (2023)

Bridging the gap between in vitro and in vivo: Dose and schedule predictions for the ATR inhibitor AZD6738
por: Checkley, Stephen, et al.
Publicado: (2015)

The schedule of ATR inhibitor AZD6738 can potentiate or abolish antitumor immune responses to radiotherapy
por: Vendetti, Frank P., et al.
Publicado: (2023)

Corrigendum: Bridging the gap between in vitro and in vivo: Dose and schedule predictions for the ATR inhibitor AZD6738
por: Checkley, Stephen, et al.
Publicado: (2016)

Optimized Treatment Schedules for Chronic Myeloid Leukemia
por: He, Qie, et al.
Publicado: (2016)

Multiple myeloma induces Mcl-1 expression and survival of myeloid-derived suppressor cells
por: De Veirman, Kim, et al.
Publicado: (2015)

Targeting MCL-1 dysregulates cell metabolism and leukemia-stroma interactions and re-sensitizes acute myeloid leukemia to BCL-2 inhibition
por: Carter, Bing Z., et al.
Publicado: (2020)

The ALK inhibitor AZD3463 effectively inhibits growth of sorafenib-resistant acute myeloid leukemia
por: Moharram, Sausan A., et al.
Publicado: (2019)

The CUL5 ubiquitin ligase complex mediates resistance to CDK9 and MCL1 inhibitors in lung cancer cells
por: Kabir, Shaheen, et al.
Publicado: (2019)

Identification of Small‐Molecule Inhibitors of the Antiapoptotic Protein Myeloid Cell Leukaemia‐1 (Mcl‐1)
por: Beekman, Andrew M., et al.
Publicado: (2015)

Increased MCL-1 expression predicts poor prognosis and disease recurrence in acute myeloid leukemia
por: Li, Xi-xi, et al.
Publicado: (2019)

Transcriptional Silencing of MCL-1 Through Cyclin-Dependent Kinase Inhibition in Acute Myeloid Leukemia
por: Tibes, Raoul, et al.
Publicado: (2019)

Rationale for a Combination Therapy Consisting of MCL1- and MEK-Inhibitors in Acute Myeloid Leukemia
por: Seipel, Katja, et al.
Publicado: (2019)

The novel combination of dual mTOR inhibitor AZD2014 and pan-PIM inhibitor AZD1208 inhibits growth in acute myeloid leukemia via HSF pathway suppression
por: Harada, Masako, et al.
Publicado: (2015)

Correction: The ALK inhibitor AZD3463 effectively inhibits growth of sorafenib-resistant acute myeloid leukemia
por: Moharram, Sausan A., et al.
Publicado: (2019)

RNA Silencing of Mcl-1 Enhances ABT-737-Mediated Apoptosis in Melanoma: Role for a Caspase-8-Dependent Pathway
por: Keuling, Angela M., et al.
Publicado: (2009)

Myeloid cell leukemia 1 (MCL-1), an unexpected modulator of protein kinase signaling during invasion
por: Young, Adelaide IJ, et al.
Publicado: (2017)

Myeloid-Specific Deletion of Mcl-1 Yields Severely Neutropenic Mice That Survive and Breed in Homozygous Form
por: Csepregi, Janka Zsófia, et al.
Publicado: (2018)

Metformin exerts a synergistic effect with venetoclax by downregulating Mcl-1 protein in acute myeloid leukemia
por: Zhou, Fang-jiao, et al.
Publicado: (2021)

Co-targeting BCL-X(L) and MCL-1 with DT2216 and AZD8055 synergistically inhibit small-cell lung cancer growth without causing on-target toxicities in mice
por: Khan, Sajid, et al.
Publicado: (2023)

The MCL-1 BH3 Helix is an Exclusive MCL-1 inhibitor and Apoptosis Sensitizer
por: Stewart, Michelle L., et al.
Publicado: (2010)

Outcomes Following ACL and Grade III MCL Injuries: Is there a Role for MCL Repair?
por: Westermann, Robert W., et al.
Publicado: (2017)

PorthoMCL: Parallel orthology prediction using MCL for the realm of massive genome availability
por: Tabari, Ehsan, et al.
Publicado: (2017)

A novel small-molecule IAP antagonist, AZD5582, draws Mcl-1 down-regulation for induction of apoptosis through targeting of cIAP1 and XIAP in human pancreatic cancer
por: Moon, Jai-Hee, et al.
Publicado: (2015)

Design and optimisation of dendrimer-conjugated Bcl-2/x(L) inhibitor, AZD0466, with improved therapeutic index for cancer therapy
por: Patterson, Claire M., et al.
Publicado: (2021)

Which Fibers of the Medial Collateral Ligament (MCL) Should Be Released in the Pie Crust Technique Applied During Knee Arthroscopy: Superficial MCL or Deep MCL?
por: Arıcan, Gökhun, et al.
Publicado: (2021)

Genetic biomarkers predict response to dual BCL-2 and MCL-1 targeting in acute myeloid leukaemia cells
por: Grundy, Martin, et al.
Publicado: (2018)

Targeting MCL-1/BCL-X(L) Forestalls the Acquisition of Resistance to ABT-199 in Acute Myeloid Leukemia
por: Lin, Kevin H., et al.
Publicado: (2016)

Arsenic trioxide synergistically promotes the antileukaemic activity of venetoclax by downregulating Mcl-1 in acute myeloid leukaemia cells
por: Cho, Hyunsoo, et al.
Publicado: (2021)

Myeloid expression of the anti-apoptotic protein Mcl1 is required in anti-myeloperoxidase vasculitis but myeloperoxidase inhibition is not protective
por: Florez-Barros, Fernanda, et al.
Publicado: (2023)

Mcl-1 Ubiquitination and Destruction
por: Inuzuka, Hiroyuki, et al.
Publicado: (2011)

A Liver-Centric Multiscale Modeling Framework for Xenobiotics
por: Sluka, James P., et al.
Publicado: (2016)

Male sterility in Mcl-1-flox mice is not due to enhanced Mcl1 protein stability
por: Ah-Cann, Casey, et al.
Publicado: (2016)

Targeting myeloid-derived suppressor cells in combination with tumor cell vaccination predicts anti-tumor immunity and breast cancer dormancy: an in silico experiment
por: Mehdizadeh, Reza, et al.
Publicado: (2023)

Inhibition of XPO1 enhances cell death induced by ABT‐199 in acute myeloid leukaemia via Mcl‐1
por: Luedtke, Daniel A., et al.
Publicado: (2018)

MCL-1ES Induces MCL-1L-Dependent BAX- and BAK-Independent Mitochondrial Apoptosis
por: Kim, Jae-Hong, et al.
Publicado: (2013)

Decoding the mechanism behind MCL-1 inhibitors: A pathway to understanding MCL-1 protein stability
por: Tantawy, Shady I., et al.
Publicado: (2023)

AZD-1222: Guillain-Barre syndrome
Publicado: (2021)

AZD-1222: Rhabdomyolysis: case report
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_5umj2gccakbk1irc12t7iadeq5